Published in FASEB J on April 26, 2007
Twenty years of cell-penetrating peptides: from molecular mechanisms to therapeutics. Br J Pharmacol (2009) 2.99
Mechanisms of cellular uptake of cell-penetrating peptides. J Biophys (2011) 2.34
Mechanisms and strategies for effective delivery of antisense and siRNA oligonucleotides. Nucleic Acids Res (2008) 2.06
Delivery of macromolecules using arginine-rich cell-penetrating peptides: ways to overcome endosomal entrapment. AAPS J (2009) 1.99
Mammalian cell penetration, siRNA transfection, and DNA transfection by supercharged proteins. Proc Natl Acad Sci U S A (2009) 1.95
A new potent secondary amphipathic cell-penetrating peptide for siRNA delivery into mammalian cells. Mol Ther (2008) 1.58
Intracellular delivery of an anionic antisense oligonucleotide via receptor-mediated endocytosis. Nucleic Acids Res (2008) 1.49
Design of a peptide-based vector, PepFect6, for efficient delivery of siRNA in cell culture and systemically in vivo. Nucleic Acids Res (2011) 1.35
Enhancing the cellular uptake of siRNA duplexes following noncovalent packaging with protein transduction domain peptides. Adv Drug Deliv Rev (2007) 1.34
Cellular uptake and intracellular trafficking of antisense and siRNA oligonucleotides. Bioconjug Chem (2011) 1.32
Improving the endosomal escape of cell-penetrating peptides and their cargos: strategies and challenges. Pharmaceuticals (Basel) (2012) 1.32
Nanoparticle-Based Delivery of RNAi Therapeutics: Progress and Challenges. Pharmaceuticals (Basel) (2013) 1.21
Cell-penetrating peptides as versatile vehicles for oligonucleotide delivery. Mol Ther (2012) 1.13
Targeting cyclin B1 through peptide-based delivery of siRNA prevents tumour growth. Nucleic Acids Res (2009) 1.06
Combined pulse electroporation--a novel strategy for highly efficient transfection of human and mouse cells. PLoS One (2010) 1.05
A cell-penetrating helical polymer for siRNA delivery to mammalian cells. Mol Ther (2012) 1.00
Chimeric aptamers in cancer cell-targeted drug delivery. Crit Rev Biochem Mol Biol (2011) 0.96
Mechanisms of nanoparticle-mediated siRNA transfection by melittin-derived peptides. ACS Nano (2013) 0.95
A peptide-based vector for efficient gene transfer in vitro and in vivo. Mol Ther (2011) 0.95
Controlling fibrous capsule formation through long-term down-regulation of collagen type I (COL1A1) expression by nanofiber-mediated siRNA gene silencing. Acta Biomater (2012) 0.92
Recent developments in peptide-based nucleic acid delivery. Int J Mol Sci (2008) 0.92
Comparison of cationic and amphipathic cell penetrating peptides for siRNA delivery and efficacy. Mol Pharm (2011) 0.91
Melittin derived peptides for nanoparticle based siRNA transfection. Biomaterials (2013) 0.91
Peptide-mediated cellular delivery of oligonucleotide-based therapeutics in vitro: quantitative evaluation of overall efficacy employing easy to handle reporter systems. Curr Pharm Des (2008) 0.91
Immunotoxins constructed with ribosome-inactivating proteins and their enhancers: a lethal cocktail with tumor specific efficacy. Curr Pharm Des (2014) 0.88
Fusogenic-oligoarginine peptide-mediated delivery of siRNAs targeting the CIP2A oncogene into oral cancer cells. PLoS One (2013) 0.84
Gene Silencing Mediated by siRNA-binding Fusion Proteins Is Attenuated by Double-stranded RNA-binding Domain Structure. Mol Ther Nucleic Acids (2012) 0.83
Plasmid DNA delivery into MDA-MB-453 cells mediated by recombinant Her-NLS fusion protein. Int J Nanomedicine (2010) 0.83
Cell penetrating peptide-modified poly(lactic-co-glycolic acid) nanoparticles with enhanced cell internalization. Acta Biomater (2015) 0.82
Transfection of infectious RNA and DNA/RNA layered vectors of semliki forest virus by the cell-penetrating peptide based reagent PepFect6. PLoS One (2013) 0.81
Hydrophobicity drives the cellular uptake of short cationic peptide ligands. Eur Biophys J (2011) 0.81
Noncovalently associated cell-penetrating peptides for gene delivery applications. Ther Deliv (2013) 0.81
Cell-Penetrating Peptides-Mechanisms of Cellular Uptake and Generation of Delivery Systems. Pharmaceuticals (Basel) (2010) 0.81
Development of cholesteryl peptide micelles for siRNA delivery. J Control Release (2013) 0.80
Delivery of nucleic acids and nanomaterials by cell-penetrating peptides: opportunities and challenges. Biomed Res Int (2015) 0.80
Targeting cancer cell-specific RNA interference by siRNA delivery using a complex carrier of affibody-displaying bio-nanocapsules and liposomes. J Nanobiotechnology (2013) 0.80
siRNA delivery to CNS cells using a membrane translocation peptide. Bioconjug Chem (2010) 0.80
Comparison of small interfering RNA (siRNA) delivery into bovine monocyte-derived macrophages by transfection and electroporation. Vet Immunol Immunopathol (2014) 0.80
pH- and ion-sensitive polymers for drug delivery. Expert Opin Drug Deliv (2013) 0.79
Peptide amphiphile containing arginine and fatty acyl chains as molecular transporters. Mol Pharm (2013) 0.79
Cell Penetrating Peptide Conjugated Chitosan for Enhanced Delivery of Nucleic Acid. Int J Mol Sci (2015) 0.79
Glycosylated cell-penetrating peptides and their conjugates to a proapoptotic peptide: preparation by click chemistry and cell viability studies. J Chem Biol (2009) 0.79
Characterization of a novel cell penetrating peptide derived from human Oct4. Cell Regen (Lond) (2014) 0.79
Technologies for investigating the physiological barriers to efficient lipid nanoparticle-siRNA delivery. J Histochem Cytochem (2013) 0.79
A role for peptides in overcoming endosomal entrapment in siRNA delivery - A focus on melittin. Biotechnol Adv (2015) 0.79
Augmenting the Efficacy of Immunotoxins and Other Targeted Protein Toxins by Endosomal Escape Enhancers. Toxins (Basel) (2016) 0.78
Fabrication of electrospun zein nanofibers for the sustained delivery of siRNA. J Mater Sci Mater Med (2015) 0.78
Structure prediction and validation of an affibody engineered for cell-specific nucleic acid targeting. Syst Synth Biol (2011) 0.77
Can RNAi-mediated hsp90α knockdown in combination with 17-AAG be a therapy for glioma? FEBS Open Bio (2013) 0.77
A HA2-Fusion tag limits the endosomal release of its protein cargo despite causing endosomal lysis. Biochim Biophys Acta (2011) 0.77
Cell-penetrating peptides: Possible transduction mechanisms and therapeutic applications. Biomed Rep (2016) 0.76
Applying horizontal gene transfer phenomena to enhance non-viral gene therapy. J Control Release (2013) 0.76
Efficient gene delivery system mediated by cis-aconitate-modified chitosan-g-stearic acid micelles. Int J Nanomedicine (2014) 0.76
Enhanced cellular uptake of lactosomes using cell-penetrating peptides. Sci Technol Adv Mater (2016) 0.75
A retro-inverso cell-penetrating peptide for siRNA delivery. J Nanobiotechnology (2017) 0.75
Trends in the Binding of Cell Penetrating Peptides to siRNA: A Molecular Docking Study. J Biophys (2017) 0.75
Selecting Molecular Recognition. What Can Existing Aptamers Tell Us about Their Inherent Recognition Capabilities and Modes of Interaction? Pharmaceuticals (Basel) (2012) 0.75
Fusogenic-oligoarginine peptide-mediated silencing of the CIP2A oncogene suppresses oral cancer tumor growth in vivo. J Control Release (2015) 0.75
Autonomously folded α-helical lockers promote RNAi. Sci Rep (2016) 0.75
Peptide nanoparticle delivery of charge-neutral splice-switching morpholino oligonucleotides. Nucleic Acid Ther (2015) 0.75
Design of a multicomponent peptide-woven nanocomplex for delivery of siRNA. PLoS One (2015) 0.75
Functional peptides for siRNA delivery. Adv Drug Deliv Rev (2016) 0.75
Functional Delivery of siRNA by Disulfide-Constrained Cyclic Amphipathic Peptides. ACS Med Chem Lett (2016) 0.75
In vitro transfection of bone marrow-derived dendritic cells with TATp-liposomes. Int J Nanomedicine (2014) 0.75
FRAX and the assessment of fracture probability in men and women from the UK. Osteoporos Int (2008) 8.75
The use of clinical risk factors enhances the performance of BMD in the prediction of hip and osteoporotic fractures in men and women. Osteoporos Int (2007) 6.44
A meta-analysis of previous fracture and subsequent fracture risk. Bone (2004) 4.92
European guidance for the diagnosis and management of osteoporosis in postmenopausal women. Osteoporos Int (2012) 4.88
Adjuvant tamoxifen therapy for early stage breast cancer and second primary malignancies. Stockholm Breast Cancer Study Group. J Natl Cancer Inst (1995) 3.79
A systematic review of hip fracture incidence and probability of fracture worldwide. Osteoporos Int (2012) 3.62
Case finding for the management of osteoporosis with FRAX--assessment and intervention thresholds for the UK. Osteoporos Int (2008) 3.44
Smoking and fracture risk: a meta-analysis. Osteoporos Int (2004) 3.08
Extent of inflammation predicts cardiovascular disease and overall mortality in seropositive rheumatoid arthritis. A retrospective cohort study from disease onset. J Rheumatol (1999) 3.02
Production of tissue factor by pancreatic islet cells as a trigger of detrimental thrombotic reactions in clinical islet transplantation. Lancet (2002) 2.76
Smoking tobacco, oral snuff, and alcohol in the etiology of squamous cell carcinoma of the head and neck: a population-based case-referent study in Sweden. Cancer (1998) 2.51
Interpretation and use of FRAX in clinical practice. Osteoporos Int (2011) 2.43
Cell-penetrating peptides. Trends Pharmacol Sci (2000) 2.42
The surgeon as a prognostic factor after the introduction of total mesorectal excision in the treatment of rectal cancer. Br J Surg (2002) 2.41
Influence of hospital- and surgeon-related factors on outcome after treatment of rectal cancer with or without preoperative radiotherapy. Br J Surg (1997) 2.21
Pitfalls in the external validation of FRAX. Osteoporos Int (2011) 2.21
A family history of fracture and fracture risk: a meta-analysis. Bone (2004) 2.13
Cardiovascular mortality in a randomized trial of adjuvant radiation therapy versus surgery alone in primary breast cancer. Int J Radiat Oncol Biol Phys (1992) 2.09
Development and use of FRAX in osteoporosis. Osteoporos Int (2010) 2.04
Prognostic significance of Ki-67 labeling index after short-term presurgical tamoxifen in women with ER-positive breast cancer. Ann Oncol (2010) 2.02
Cell penetration by transportan. FASEB J (1998) 1.93
Adjuvant goserelin and ovarian preservation in chemotherapy treated patients with early breast cancer: results from a randomized trial. Breast Cancer Res Treat (2009) 1.90
Development and application of a Japanese model of the WHO fracture risk assessment tool (FRAX). Osteoporos Int (2008) 1.77
Mortality by laterality of the primary tumour among 55,000 breast cancer patients from the Swedish Cancer Registry. Br J Cancer (1990) 1.73
Impact of a surgical training programme on rectal cancer outcomes in Stockholm. Br J Surg (2005) 1.68
Cargo delivery kinetics of cell-penetrating peptides. Biochim Biophys Acta (2001) 1.64
The Stockholm I trial of preoperative short term radiotherapy in operable rectal carcinoma. A prospective randomized trial. Stockholm Colorectal Cancer Study Group. Cancer (1995) 1.60
Position sense acuity is diminished following repetitive low-intensity work to fatigue in a simulated occupational setting. Eur J Appl Physiol (2000) 1.57
Impaired postoperative leucocyte counts after preoperative radiotherapy for rectal cancer in the Stockholm III Trial. Br J Surg (2013) 1.56
Effect of blood tamoxifen concentrations on surrogate biomarkers in a trial of dose reduction in healthy women. J Clin Oncol (1999) 1.53
Estimation of the parenchymal-cell content of the parathyroid gland, using density-gradient columns. Preliminary report. Acta Pathol Microbiol Scand A (1977) 1.52
Remaining lifetime and absolute 10-year probabilities of osteoporotic fracture in Swiss men and women. Osteoporos Int (2008) 1.45
Cell penetrating PNA constructs regulate galanin receptor levels and modify pain transmission in vivo. Nat Biotechnol (1998) 1.44
The burden of hospitalised fractures in Sweden. Osteoporos Int (2004) 1.41
Ten-year fracture probability identifies women who will benefit from clodronate therapy--additional results from a double-blind, placebo-controlled randomised study. Osteoporos Int (2008) 1.39
Malignant and benign human mammary disease: estrogen binding in relation to clinical data. Cancer (1974) 1.39
The Stockholm II trial on preoperative radiotherapy in rectal carcinoma: long-term follow-up of a population-based study. Cancer (2001) 1.39
Normocalcemic hyperparathyroidism, kidney stones, and idiopathic hypercalciuria. Surgery (1975) 1.38
Tumour location and the effects of preoperative radiotherapy in the treatment of rectal cancer. Br J Surg (2001) 1.37
Galanin modulation of seizures and seizure modulation of hippocampal galanin in animal models of status epilepticus. J Neurosci (1998) 1.36
The potential impact of new National Osteoporosis Foundation guidance on treatment patterns. Osteoporos Int (2009) 1.36
Deletion analogues of transportan. Biochim Biophys Acta (2000) 1.35
The epidemiology of biopsy-positive giant cell arteritis: special reference to cyclic fluctuations. Rheumatology (Oxford) (1999) 1.34
The use of multiple sites for the diagnosis of osteoporosis. Osteoporos Int (2006) 1.31
Phosphate status affects the gene expression, protein content and enzymatic activity of UDP-glucose pyrophosphorylase in wild-type and pho mutants of Arabidopsis. Planta (2001) 1.29
The binding of estradiol-17beta to human breast cancers and other tissues in vitro. Cancer Res (1970) 1.27
Construction of a FRAX® model for the assessment of fracture probability in Canada and implications for treatment. Osteoporos Int (2010) 1.25
Fracture prediction and calibration of a Canadian FRAX® tool: a population-based report from CaMos. Osteoporos Int (2010) 1.24
Galanin reduces release of endogenous excitatory amino acids in the rat hippocampus. Eur J Pharmacol (1993) 1.24
Actions on gamma-motoneurones elicited by electrical stimulation of group I muscle afferent fibres in the hind limb of the cat. J Physiol (1983) 1.24
The influence of group II muscle afferents and low threshold skin afferents on dynamic fusimotor neurones to the triceps surae of the cat. Brain Res (1977) 1.22
Influence of prior and subsequent pregnancy on breast cancer prognosis. J Clin Oncol (1995) 1.21
Actions on gamma-motoneurones elicited by electrical stimulation of group III muscle afferent fibres in the hind limb of the cat. J Physiol (1983) 1.20
Nuclear DNA-content of parathyroid cells in adenomas, hyperplastic and normal glands. Acta Pathol Microbiol Scand A (1977) 1.20
FRAX assessment of osteoporotic fracture probability in Switzerland. Osteoporos Int (2009) 1.19
Sucrose and light regulation of a cold-inducible UDP-glucose pyrophosphorylase gene via a hexokinase-independent and abscisic acid-insensitive pathway in Arabidopsis. Biochem J (2001) 1.18
Spine-hip discordance and fracture risk assessment: a physician-friendly FRAX enhancement. Osteoporos Int (2010) 1.18
Localized muscle fatigue decreases the acuity of the movement sense in the human shoulder. Med Sci Sports Exerc (1999) 1.17
A fatal case of pup infection with minute virus of canines (MVC). J Vet Diagn Invest (1996) 1.17
Actions on gamma-motoneurones elicited by electrical stimulation of group II muscle afferent fibres in the hind limb of the cat. J Physiol (1983) 1.17
Glutamate NMDAR1 receptors localised to nerves in human Achilles tendons. Implications for treatment? Knee Surg Sports Traumatol Arthrosc (2001) 1.16
Receptor-receptor interactions within receptor mosaics. Impact on neuropsychopharmacology. Brain Res Rev (2008) 1.15
The potential impact of the National Osteoporosis Foundation guidance on treatment eligibility in the USA: an update in NHANES 2005-2008. Osteoporos Int (2011) 1.14
Prognostic significance of DNA-analysis by flow cytometry in non-Hodgkin's lymphoma. Hematol Oncol (1986) 1.13
Malignant melanoma of the vulva and vagina. Trends in incidence, age distribution, and long-term survival among 245 consecutive cases in Sweden 1960-1984. Cancer (1993) 1.13
Interaction and structure induction of cell-penetrating peptides in the presence of phospholipid vesicles. Biochim Biophys Acta (2001) 1.13
The parathyroid glands in experimentally induced hypergastrinemia in the rat. Scand J Gastroenterol (1977) 1.12
The effects of a FRAX revision for the USA. Osteoporos Int (2009) 1.12
Galanin--a neuroendocrine peptide. Crit Rev Neurobiol (1993) 1.11
Fusimotor reflexes in triceps surae elicited by natural stimulation of muscle afferents from the cat ipsilateral hind limb. J Physiol (1982) 1.10
Application of the National Osteoporosis Foundation Guidelines to postmenopausal women and men: the Framingham Osteoporosis Study. Osteoporos Int (2010) 1.09
Fracture risk assessment without bone density measurement in routine clinical practice. Osteoporos Int (2011) 1.08
Reduction of postoperative morbidity and mortality in patients with rectal cancer following the introduction of a colorectal unit. Br J Surg (2001) 1.08
Limits on neutrino emission from gamma-ray bursts with the 40 string IceCube detector. Phys Rev Lett (2011) 1.08
Parathyroid adenomas and glands in normocalcemic hyperparathyroidism. A light microscopic study. Am J Pathol (1976) 1.08
Translocation properties of novel cell penetrating transportan and penetratin analogues. Bioconjug Chem (2000) 1.07
Estimation of parenchymal cell content of human parathyroid glands using the image analyzing computer technique. Am J Pathol (1978) 1.07
Monoclonal antibodies with exclusive reactivity against parathyroid cells and tubule cells of the kidney. Proc Natl Acad Sci U S A (1987) 1.06
Letter: Dysproteinemia, malignancy, and hyperparathyroidism. Ann Intern Med (1975) 1.06
Galanin and galanin antagonists: molecular and biochemical perspectives. Trends Pharmacol Sci (1992) 1.06
Galanin-mediated control of pain: enhanced role after nerve injury. Proc Natl Acad Sci U S A (1992) 1.06
Studies on the non-adenomatous glands in patients with a solitary parathyroid adenoma. Ups J Med Sci (1976) 1.05
M-15: high-affinity chimeric peptide that blocks the neuronal actions of galanin in the hippocampus, locus coeruleus, and spinal cord. Proc Natl Acad Sci U S A (1991) 1.05
Complex co-localization of chromogranins and neurohormones in the human gastrointestinal tract. J Histochem Cytochem (1997) 1.03
Axon-collateral activation by dorsal spinocerebellar tract fibres of group I relay cells of nucleus Z in the cat medulla oblongata. J Physiol (1977) 1.03
A meta-analysis of the effect of strontium ranelate on the risk of vertebral and non-vertebral fracture in postmenopausal osteoporosis and the interaction with FRAX(®). Osteoporos Int (2011) 1.02
Radiotherapy, chemotherapy, and tamoxifen as adjuncts to surgery in early breast cancer: a summary of three randomized trials. Int J Radiat Oncol Biol Phys (1989) 1.02
Calibration of FRAX ® 3.1 to the Dutch population with data on the epidemiology of hip fractures. Osteoporos Int (2011) 1.02
Biologic activity of tamoxifen at low doses in healthy women. J Natl Cancer Inst (1998) 1.02
Guidance for the adjustment of FRAX according to the dose of glucocorticoids. Osteoporos Int (2011) 1.00
Position sense testing: influence of starting position and type of displacement. Arch Phys Med Rehabil (2000) 1.00
Galanin-receptor ligand M40 peptide distinguishes between putative galanin-receptor subtypes. Proc Natl Acad Sci U S A (1993) 1.00
Ultrasonic appearance of adenomatous and hyperplastic parathyroid glands. Acta Radiol Diagn (Stockh) (1984) 0.99
Intrathyroidal concentrations of methimazole in patients with Graves' disease. J Clin Endocrinol Metab (1983) 0.99
Occupational exposures and squamous cell carcinoma of the oral cavity, pharynx, larynx, and oesophagus: a case-control study in Sweden. Occup Environ Med (1998) 0.98
Linear and cyclic N-terminal galanin fragments and analogs as ligands at the hypothalamic galanin receptor. Int J Pept Protein Res (1991) 0.98
Immune-mediated complications in patients with myelodysplastic syndromes--clinical and cytogenetic features. Eur J Haematol (1995) 0.98
Non-Hodgkin lymphoma. Multivariate analysis of prognostic factors including fraction of S-phase cells. Acta Oncol (1987) 0.97